University of Surrey

Test tubes in the lab Research in the ATI Dance Research

Intraocular methotrexate can induce extended remission in some patients in noninfectious uveitis

Taylor, SRJ, Banker, A, Schlaen, A, Couto, C, Matthe, E, Joshi, L, Menezo, V, Nguyen, E, Tomkins-Netzer, O, Bar, A, Morarji, J, McCluskey, P and Lightman, S (2013) Intraocular methotrexate can induce extended remission in some patients in noninfectious uveitis Retina, 33 (10). pp. 2149-2154.

Full text not available from this repository.

Abstract

PURPOSE: To assess the outcomes of the intravitreal administration of methotrexate in uveitis. METHODS: Multicenter, retrospective interventional case series of patients with noninfectious uveitis. Thirty-eight eyes of 30 patients were enrolled, including a total of 54 intravitreal injections of methotrexate at a dose of 400 μg in 0.1 mL. The primary outcome measure was visual acuity. Secondary outcome measures included control of intraocular inflammation and cystoid macular edema, time to relapse, development of adverse events, and levels of systemic corticosteroid and immunosuppressive therapy. RESULTS: Methotrexate proved effective in controlling intraocular inflammation and improving vision in 30 of 38 eyes (79%). The side effect profile was good, with no reported serious ocular adverse events and only one patient having an intraocular pressure of >21 mmHg. Of the 30 eyes that responded to treatment, 8 relapsed, but 22 (73%) entered an extended period of remission, with the Kaplan-Meier estimate of median time to relapse for the whole group being 17 months. The eight eyes that relapsed were reinjected and all responded to treatment. One eye relapsed at 3 months, but 7 eyes again entered extended remission. Of the 14 patients on systemic therapy at the start of the study, 8 (57%) were able to significantly reduce this following intravitreal methotrexate injection. CONCLUSION: In patients with uveitis and uveitic cystoid macular edema, intravitreal MTX can effectively improve visual acuity and reduce cystoid macular edema and, in some patients, allows the reduction of immunosuppressive therapy. Some patients relapse at 3 to 4 months, but a large proportion (73%) enter an extended period of remission of up to 18 months. This larger study extends the results obtained from previous smaller studies suggesting the viability of intravitreal methotrexate as a treatment option in uveitis.

Item Type: Article
Authors :
NameEmailORCID
Taylor, SRJs.r.taylor@surrey.ac.ukUNSPECIFIED
Banker, AUNSPECIFIEDUNSPECIFIED
Schlaen, AUNSPECIFIEDUNSPECIFIED
Couto, CUNSPECIFIEDUNSPECIFIED
Matthe, EUNSPECIFIEDUNSPECIFIED
Joshi, LUNSPECIFIEDUNSPECIFIED
Menezo, VUNSPECIFIEDUNSPECIFIED
Nguyen, EUNSPECIFIEDUNSPECIFIED
Tomkins-Netzer, OUNSPECIFIEDUNSPECIFIED
Bar, AUNSPECIFIEDUNSPECIFIED
Morarji, JUNSPECIFIEDUNSPECIFIED
McCluskey, PUNSPECIFIEDUNSPECIFIED
Lightman, SUNSPECIFIEDUNSPECIFIED
Date : 1 November 2013
Identification Number : https://doi.org/10.1097/IAE.0b013e31828ac07d
Depositing User : Symplectic Elements
Date Deposited : 17 May 2017 10:41
Last Modified : 17 May 2017 14:51
URI: http://epubs.surrey.ac.uk/id/eprint/828774

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year


Information about this web site

© The University of Surrey, Guildford, Surrey, GU2 7XH, United Kingdom.
+44 (0)1483 300800